Mitochondrial Dysfunction Drives Age-Related Degeneration of the Thoracic Aorta

Dhanekula, A. S., Harrison, B., Pharaoh, G., Mattson-Hughes, A., Tarantini, S., Stuppard, R., DeRoo, S., Burke, C. R., Hwang, B., Pal, J. D., Mulligan, M. S., Marcinek, D.

University of Washington · biorxiv

Paper

Abstract

This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks. ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux. ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice. Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes. Mitochondrial dysfunction thus drives aortic aging and is a potential therapeutic target for future study.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta. This study addresses a root cause of aging by investigating mitochondrial function and its therapeutic potential in a key age-related vascular condition, contributing to the understanding of aging mechanisms.

Author of this paper? Send a correction.